CVac

DGAP-News: CureVac Appoints Klaus Edvardsen as Chief Development Officer

Retrieved on: 
Wednesday, June 2, 2021
CureVac, Tübingen, Health care, Health, Pharmaceutical companies, Merck Group, CVac, Ingmar Hoerr, CVnCoV, CureVac, CVNCOV, CUREVAC

TBINGEN, Germany / BOSTON, USA - June 2, 2021 - CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the appointment of Klaus Edvardsen, MD, PhD, as Chief Development Officer.

Key Points: 
  • TBINGEN, Germany / BOSTON, USA - June 2, 2021 - CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the appointment of Klaus Edvardsen, MD, PhD, as Chief Development Officer.
  • "We are very happy to welcome Dr. Edvardsen to the CureVac leadership team," said Jean Stphenne, Chairman of the Supervisory Board of CureVac.
  • "We are very pleased that Klaus is joining us in highly dynamic times for the company," said Dr. Franz-Werner Haas, Chief Executive Officer of CureVac.
  • Dr. Edvardsen joins CureVac from Merck KGaA, where he led early- and late-stage global oncology development as a Senior Vice President and Head of Global Oncology Development.

SOTIO to Present Biomarker Data from its SOV01 – DCVAC/OvCa Phase 2 Study in 1st line Ovarian Cancer at the 2021 ASCO Annual Meeting

Retrieved on: 
Tuesday, May 11, 2021
Clinical medicine, Medicine, Cancer, Gynaecological cancer, Oncology, Cancer treatments, Debulking, Surgical oncology, Ovarian cancer, CVac, Surface epithelial-stromal tumor, Chemotherapy

b'SOTIO , a clinical stage immune-oncology company owned by PPF Group, today announced the presentation of a virtual poster at the 2021 ASCO Annual Meeting.

Key Points: 
  • b'SOTIO , a clinical stage immune-oncology company owned by PPF Group, today announced the presentation of a virtual poster at the 2021 ASCO Annual Meeting.
  • The presentation focuses on potentially predictive biomarker data from a phase 2 study of SOTIO\xe2\x80\x99s dendritic cell vaccine (DCVAC/OvCa) combined with chemotherapy in patients with newly diagnosed epithelial ovarian carcinoma after primary debulking surgery.\nSOTIO\xe2\x80\x99s DCVAC Program is a cell therapy platform designed to improve efficacy compared to earlier generations of dendritic cell therapies by targeting multiple antigens and applying an immune-stimulatory technique.
  • SOTIO has created this vertically integrated, personalized cell therapy platform to enable the efficient manufacturing of product doses for one year of treatment at commercially attractive costs.\nTitle: Dendritic cell vaccine (DCVAC) combined with chemotherapy (CMT) in patients with newly diagnosed epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Biomarker exploratory analysis of a phase 2, open-label, randomized, multicenter trial\nPresenting Author: Lukas Rob, MD, PhD, University Hospital Kralovske Vinohrady (Prague, Czech Republic)\nA copy of the presentation materials can be accessed on the SOTIO website once the presentation concludes, and a recorded oral presentation focused on the data will be hosted on the online ASCO Media Library.\nSOV01 is a randomized, open-label, three-arm multicenter Phase II clinical trial evaluating DCVAC/OvCa in combination with first-line standard chemotherapy in women with newly diagnosed epithelial ovarian cancer following radical debulking surgery.\n'

DGAP-News: CureVac Announces Closing of $450 million Follow-on Public Offering of Common Shares

Retrieved on: 
Tuesday, February 2, 2021
Finance, Financial services, Companies, CureVac, Tübingen, Evercore, Kempen & Co, CVac, NASDAQ, UBS, Offering, Investment banking

TBINGEN, Germany / BOSTON, USA - February 2, 2021 - CureVac N.V. (Nasdaq: CVAC) ("CureVac" or the "Company"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today the closing of its follow-on public offering of 5,000,000 common shares, at a public offering price of $90.00 per common share, for total gross proceeds of approximately $450 million.

Key Points: 
  • TBINGEN, Germany / BOSTON, USA - February 2, 2021 - CureVac N.V. (Nasdaq: CVAC) ("CureVac" or the "Company"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today the closing of its follow-on public offering of 5,000,000 common shares, at a public offering price of $90.00 per common share, for total gross proceeds of approximately $450 million.
  • BofA Securities, Jefferies and Evercore ISI are acting as joint book-running managers for the offering.
  • UBS Investment Bank, Guggenheim Securities, Berenberg and Kempen & Co are acting as passive book-running managers for the offering.
  • CureVac had its initial public offering on the New York Nasdaq in August 2020.

DGAP-News: CureVac Announces Pricing of $450 million Follow-on Public Offering of Common Shares

Retrieved on: 
Thursday, January 28, 2021
CureVac, Tübingen, Initial public offering, Finance, Financial markets, Stock market, Follow-on offering, CVac, NASDAQ

TBINGEN, Germany/ BOSTON, USA - January 28, 2021 - CureVac N.V. (Nasdaq: CVAC) ("CureVac" or the "Company"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today the pricing of its follow-on public offering of 5,000,000 common shares at a public offering price of $90.00 per common share, for total gross proceeds of approximately $450 million.

Key Points: 
  • TBINGEN, Germany/ BOSTON, USA - January 28, 2021 - CureVac N.V. (Nasdaq: CVAC) ("CureVac" or the "Company"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today the pricing of its follow-on public offering of 5,000,000 common shares at a public offering price of $90.00 per common share, for total gross proceeds of approximately $450 million.
  • In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 750,000 common shares at the public offering price, less underwriting discounts and commissions.
  • All of the common shares are being offered by CureVac.
  • CureVac had its initial public offering on the New York Nasdaq in August 2020.

DGAP-News: CureVac : CureVac Establishes European-Based Network to Ramp Up Manufacturing of its COVID-19 Vaccine Candidate, CVnCoV

Retrieved on: 
Tuesday, November 17, 2020
CureVac, Tübingen, Medicine, Health, Medical research, COVID-19 vaccine, CVac, Vaccines, Ingmar Hoerr

CureVac : CureVac Establishes European-Based Network to Ramp Up Manufacturing of its COVID-19 Vaccine Candidate, CVnCoV

Key Points: 
  • CureVac : CureVac Establishes European-Based Network to Ramp Up Manufacturing of its COVID-19 Vaccine Candidate, CVnCoV
    The issuer is solely responsible for the content of this announcement.
  • CureVac Establishes European-Based Network to Ramp Up Manufacturing of its COVID-19 Vaccine Candidate, CVnCoV
    TBINGEN, Germany/ BOSTON, USA - November 17, 2020 - CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), announced today that it is accelerating the expansion of its manufacturing network to deliver pandemic-scale volumes of its COVID-19 vaccine candidate, CVnCoV.
  • CureVac aims to build a broad and integrated European vaccine manufacturing network with highly experienced CDMO (Contract Development and Manufacturing Organization) partners for each of the key manufacturing steps for CVnCoV.
  • CureVac's CVnCoV manufacturing network will leverage expertise and capacity across Germany, France, the Netherlands, Belgium, Spain and Austria, as well as potentially Sweden, Poland, Italy and Ireland.

DGAP-News: dievini Hopp BioTech Congratulates CureVac on Successful Nasdaq IPO

Retrieved on: 
Wednesday, August 19, 2020
States of Germany, CureVac, Dietmar Hopp, Computer companies, SAP, Companies, Hopp, CVac, Walldorf, dievini, CureVac

WALLDORF, Germany - 19 August 2020 - dievini Hopp BioTech holding GmbH & Co. KG (dievini) congratulates portfolio company CureVac N.V. (Nasdaq: CVAC), a pioneer in the development of mRNA-based drugs, on its recent IPO on the U.S. Nasdaq stock exchange, citing it as a true European biotech success story.

Key Points: 
  • WALLDORF, Germany - 19 August 2020 - dievini Hopp BioTech holding GmbH & Co. KG (dievini) congratulates portfolio company CureVac N.V. (Nasdaq: CVAC), a pioneer in the development of mRNA-based drugs, on its recent IPO on the U.S. Nasdaq stock exchange, citing it as a true European biotech success story.
  • dievini remains the largest shareholder in CureVac with just under 50% and has invested further EUR 100 million in the IPO.
  • Dietmar Hopp, co-founder of dievini, said: "CureVac was one of the first investments in our portfolio, and I am pleased to see how the company has developed over the years, culminating in the recent IPO.
  • dievini Hopp BioTech holding GmbH & Co. KG is a holding company of SAP co-founder Dietmar Hopp with an investment focus on innovative biotechnology companies.

DGAP-News: CureVac : CureVac Announces Proposed Initial Public Offering of Common Shares

Retrieved on: 
Monday, August 10, 2020
Initial public offering, Financial economics, Finance, Money, Corporate finance, CureVac, CVac, Underwriting, Public offering

TBINGEN, Germany/ BOSTON, USA - August 10, 2020 - CureVac B.V. ("CureVac" or the "Company"), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today that it intends to offer and sell in an underwritten public offering of 13,333,333 common shares.

Key Points: 
  • TBINGEN, Germany/ BOSTON, USA - August 10, 2020 - CureVac B.V. ("CureVac" or the "Company"), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today that it intends to offer and sell in an underwritten public offering of 13,333,333 common shares.
  • In addition, the Company expects to grant the underwriters a 30-day option to purchase up to an additional 1,999,999 common shares at the initial public offering price, less underwriting discounts and commissions.
  • The initial public offering price is expected to be between $14.00 and $16.00 per common share.
  • CureVac has applied to list its common shares on The Nasdaq Global Market under the ticker symbol "CVAC".